Molecular insights into the interaction between human nicotinamide phosphoribosyltransferase and Toll-like receptor 4.
DAMP
NAD biosynthesis
NAMPT
Toll-like receptor 4 (TLR4)
inflammation
receptor-interacting protein (RIP)
surface plasmon resonance (SPR)
Journal
The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
10
09
2021
revised:
23
01
2022
accepted:
25
01
2022
pubmed:
6
2
2022
medline:
16
4
2022
entrez:
5
2
2022
Statut:
ppublish
Résumé
The secreted form of the enzyme nicotinamide phosphoribosyltransferase (NAMPT), which catalyzes a key reaction in intracellular NAD biosynthesis, acts as a damage-associated molecular pattern triggering Toll-like receptor 4 (TLR4)-mediated inflammatory responses. However, the precise mechanism of interaction is unclear. Using an integrated approach combining bioinformatics and functional and structural analyses, we investigated the interaction between NAMPT and TLR4 at the molecular level. Starting from previous evidence that the bacterial ortholog of NAMPT cannot elicit the inflammatory response, despite a high degree of structural conservation, two positively charged areas unique to the human enzyme (the α1-α2 and β1-β2 loops) were identified as likely candidates for TLR4 binding. However, alanine substitution of the positively charged residues within these loops did not affect either the oligomeric state or the catalytic efficiency of the enzyme. The kinetics of the binding of wildtype and mutated NAMPT to biosensor-tethered TLR4 was analyzed. We found that mutations in the α1-α2 loop strongly decreased the association rate, increasing the K
Identifiants
pubmed: 35120922
pii: S0021-9258(22)00109-0
doi: 10.1016/j.jbc.2022.101669
pmc: PMC8892085
pii:
doi:
Substances chimiques
Cytokines
0
NF-kappa B
0
TLR4 protein, human
0
Toll-Like Receptor 4
0
NAD
0U46U6E8UK
Nicotinamide Phosphoribosyltransferase
EC 2.4.2.12
nicotinamide phosphoribosyltransferase, human
EC 2.4.2.12
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
101669Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article.